Uses of 5-Methyltetrahydrofolic Acid
5-methyltetrahydrofolic acid addresses the issue of unmetabolized folic acid causing congenital heart disease by ensuring normal embryonic heart development, providing a more effective prevention method than traditional folic acid supplementation.
Patent Information
- Application Number
- JP2022514615
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-03
- Filing Date
- 2020-09-03
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2040-09-03
AI Technical Summary
Existing folic acid supplementation during pregnancy is associated with increased incidence of congenital heart disease due to unmetabolized folic acid, leading to inconsistent and contradictory research findings regarding its effectiveness in preventing such defects.
The use of 5-methyltetrahydrofolic acid, which is not teratogenic and can prevent congenital heart disease when taken during pregnancy, is proposed as a substitute for folic acid.
5-methyltetrahydrofolic acid effectively prevents congenital heart disease in newborns by maintaining normal embryonic heart development and reducing the risk associated with folic acid supplementation.
Smart Images

Figure 0007591299000006 
Figure 0007591299000007 
Figure 0007591299000008
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of medicine and relates to a novel use of a composition containing 5-methyltetrahydrofolic acid in the preparation of a drug or health functional food for preventing congenital heart disease in newborns, miscarriage, and stillbirth in women preparing for pregnancy and / or during pregnancy. [Background technology]
[0002] Congenital heart disease (CHD) has become the leading cause of birth defects and the most common heart disease in childhood. It has seriously harmed the lives and quality of life of sick children and is an important cause of death in children aged 0-5 years.
[0003] Congenital heart disease is classified into multiple subtypes, with ventricular septal defect (VSD), atrial septal defect (ASD), patent ductus arteriosus (PDA), tetralogy of Fallot (TOF), transposition of the great arteries (TGA), tricuspid atresia or stenosis, and pulmonary stenosis (PS) being the top seven most common subtypes.
[0004] At present, the effectiveness of folic acid in preventing neural tube defects has already been confirmed, but there is controversy among experts in various countries regarding the prevention of congenital heart disease using folic acid. Currently, most scholars believe that folic acid supplementation is helpful in preventing congenital heart disease, and some even suggest that congenital heart disease should be prevented by using higher doses of folic acid [Huhta JC, Linask K. When should we prescribe high-dose folic acid to prevent congenital heart defects?[J]. Current Opinion in Cardiology, 2015, 30(1): 125-131.]. Folic acid means pteroylglutamic acid, a synthetic folic acid, also known as vitamin B9 and vitamin M, and its English name is folic acid. In medicinal use, folic acid is used to prevent neural tube malformations in newborns and prevent and treat megaloblastic anemia, and the World Health Organization recommends that the daily intake of lactating mothers and pregnant women be 400 μg / day. When large amounts of folic acid are ingested, unmetabolized folic acid and reduced folic acid (5-methyltetrahydrofolic acid and its derivatives) are present in the blood circulation.
[0005] Folic acid is a synthetic oxidized form and is not found in natural foods. Folic acid cannot be utilized by the human body unless it is converted to tetrahydrofolic acid by human dihydrofolate reductase (DHFR), but this process is slow in the human body. Research has shown that the metabolic rate of folic acid in the human liver is 1.79% of that of rats at physiological pH, so when folic acid is taken, unmetabolized folic acid may be detected in the blood, and scholars have reported that unmetabolized folic acid can be detected in plasma several hours after taking 200 μg or more of folic acid [Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci US A. 2009;106(36):15424-15429.]. In addition, accumulation of unmetabolized folic acid in cells may decrease DHFR activity.
[0006] Looking back at existing studies on the relationship between folic acid and pre-existing heart disease, some early North American studies are worth mentioning. One of these studies, conducted by telephone interviews with 207 mothers who gave birth in California between 1987 and 1998 with conotruncal heart defects and 481 randomly selected mothers without malformations, showed that infants whose mothers consumed more vitamins and folic acid-fortified grains had a reduced risk of conotruncal heart disease [Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM and Lammer EJ. Maternal periconeptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. American Journal of Medical Genetics. 1995;59:536-545.]. However, the estimates for this study were not remarkable. A subsequent study in California from 1999 to 2004 found no protective effect of folic acid multivitamins against conotruncal heart defects [Shaw GM, Carmichael SL, Yang W and Lammer EJ. Periconceptional nutrient intakes and risks of conotruncal heart defects. Birth Defects Res A Clin Mol Teratol. 2010;88:144-51.]. A controlled study conducted in hospitals in Boston, Canada, Philadelphia, USA, and Toronto, Canada from 1993 to 1996 found no significant association between prenatal intake of folic acid-containing vitamins and the type of heart defects [Werler MM, Hayes C, Louik C, Shapiro S and Mitchell AA. Multivitamin supplementaion and risk of birth defects. American Journal of Epidemiology. 1999;150:675-682.].A Baltimore-Washington study found no preventive effect from preconception supplementation with 400 mg / day of folic acid [Scanlon KS, Ferencz C, Loffredo CA, et al. Preconceptional folate intake and malformations of the cardiac outflow tract. Baltimore-Washington Infant Study Group.[J]. Epidemiology, 1998, 9(1):95-98.] A report from the National Birth Defects Prevention Study from 1997 to 2004 noted that a multicenter study of the combined effects of maternal diabetes and multiple vitamins, including folic acid, on multiple heart defects showed an unadjusted OR value of 0.95 (95% CI 0.85-1.06), indicating that the relationship between the two is not large [Correa A, Gilboa SM, Botto LD, Moore CA, Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK, Reece EA and National Birth Defects Prevention S. Lack of periconceptional vitamins or supplements that contain folic acid and diabetes mellitus-associated birth defects. Am J Obstet Gynecol. 2012;206:218 e1-13.].
[0007] A Hungarian research team pointed out that in a randomized controlled study conducted in 1984-1991 to prevent neural tube defects by supplementing with folic acid, the experimental group took a multivitamin containing 0.8 mg of folic acid from one month before pregnancy to three months after pregnancy, and found that the control group had a significantly reduced incidence of neural tube defects and a 40% reduction in the incidence of preconceptional heart disease [Czeizel, Andrew E. Prevention of congenital abnormalities by periconceptional multivitamin supplementation.[J]. Bmj, 1993, 306(6893):1645-1648.]. However, the above study had flaws, such as the small number of preconceptional heart disease cases included, with only 10 cases of exposed heart defects and 17 cases of unexposed heart defects. Subsequent evaluation studies have found that influenza and common cold complications are associated with a higher risk of conotruncal abnormalities in pregnant women and that high doses of folic acid can reduce the risk of conotruncal abnormalities [Csaky-Szunyogh, Melinda, Vereczkey A , Kosa, Zsolt, et al. Risk and protective factors in the origin of conotruncal defects of heart--a population-based case-control study.[J]. American Journal of Medical Genetics Part A, 2013, 161(10):2444-2452.].
[0008] A 1997-1998 study in Australia found no association between folate and risk of offspring heart defects [Bower C, Miller M, Payne J, Serna P. Folate intake and the primary prevention of non-neural birth defects. Aust NZJ Public Health. 2006;30(3):258-261.] A case-control study in the northern Netherlands noted that the risk of heart defects in infants born to women who used folic acid was reduced by approximately 20%, but in an analysis of cardiac subtypes, the risk of atrioventricular septal defect was increased with folic acid supplementation, with an OR value of 1.28 (95% CI 0.33-4.95) [van Beynum IM, Kapusta L, Bakker MK, den Heijer M, Blom HJ, de Walle HE. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J. 2010;31(4):464-471. ].
[0009] A Norwegian research team [Leirgul E, Gildestad T, Nilsen RM, et al. Periconceptional Folic Acid Supplementation and Infant Risk of Congenital Heart Defects in Norway 1999-2009[J]. Paediatric and Perinatal Epidemiology, 2015, 29(5):391-400.] pointed out that folic acid supplementation during the pregnancy preparation period did not lead to a reduction in the incidence of severe congenital heart defects. In addition, it was found that the risk of developing septal defect-type congenital heart defects increased by 20% after supplementation with 0.4 mg of folic acid. Furthermore, a case-analysis study of 197,123 infants from Norway in 2000-2009 and Denmark in 1996-2003, some of whose data may include those from the aforementioned studies, concluded that folic acid was not associated with the risk of offspring congenital heart defects (including major defects, conus defects, or ventricular septal defects) [Oyen N, Olsen SF, Basit S, et al. Association Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norway. J Am Heart Assoc. 2019;8(6):e011615.].
[0010] Scholars also collected statistics on approximately 200,000 births in the Canadian province of Alberta between 1995 and 2002 [Bedard T, Lowry RB, Sibbald B, et al. Folic acid fortification and the birth prevalence of congenital heart defect cases in Alberta, Canada[J]. Birth Defects Research Part A: Clinical and Molecular Teratology, 2013, 97(8):564-570.] and found that the total incidence of congenital heart defect did not change before and after the implementation of the folic acid fortification policy in 1998.
[0011] In China, several studies have also been conducted on periconceptional heart defects using folic acid. Case-control studies in hospitals in Guangdong, Hubei, Fujian, and Shanxi have shown that folic acid supplements can reduce the risk of periconceptional heart defects by 65% [Li X, Li S, Mu D, et al. The association between periconceptional folic acid supplementation and congenital heart defects: a case-control study in China. Prev Med. 2013;56(6):385-389.]. Chinese scholars [Baohong M, Jie Q, Nan Z, et al. Maternal folic acid supplementation and dietary folate intake and congenital heart defects[J]. PLOS ONE, 2017, 12(11):e0187996-.] pointed out that in a birth cohort study in Gansu Province from 2010 to 2012, folic acid reduced the probability of newborns suffering from congenital heart disease, and the risk of pregnant women with low intakes giving birth to children with congenital heart disease was almost twice as high as that of the folic acid supplementation group. It should be noted that the above study also showed that consuming folic acid greater than 221.03 μg / day increased the risk of atrioventricular septal defect, with an OR value of 1.20 (95% CI 0.58-2.51). A Guangdong study conducted from 2004 to 2016, based on approximately 8,379 cases of pre-existing heart disease and 6,918 control cases, suggested that the use of folic acid by pregnant women early in pregnancy could lead to a lower risk of coronary heart disease [Qu Y, Lin S, Zhuang J, et al. First-Trimester Maternal Folic Acid Supplementation Reduced Risks of Severe and Most Congenital Heart Diseases in Offspring: A Large Case-Control Study. J Am Heart Assoc. 2020;9(13):e015652.].The reason why the results of this data are inconsistent with previous studies is that before the free folic acid supplementation program in China in 2010, few pregnant women used folic acid, and their folic acid levels were originally low. This study did not investigate the folic acid levels in the diet of pregnant women and their own folic acid levels, and did not consider related factors such as dosage. The authors also acknowledge that the number of cases with folic acid subtypes among the statistical cases was small, and may not be representative.
[0012] A prerequisite for examining causality is research designed to provide specific information on the use of folic acid supplements and the risk of infant heart defects, but the results of some of the studies mentioned above are contradictory due to design, bias, and confounds, and may be interpreted as differences in folic acid levels in regional dietary habits.
[0013] From the above, the effect of folic acid on cardiac arrest is still questionable. Of the 15 clinical studies mentioned above on folic acid related to cardiac arrest, only 8 clearly support that folic acid is useful for preventing cardiac arrest, of which the number of Hungarian study cases is small, and the research reports from the Netherlands, Norway and China support that folic acid can help reduce the risk of cardiac arrest, but the details of the reports also show that folic acid supplementation may increase the risk of atrioventricular septal defect. The above studies are merely clinical data statistics and telephone follow-up surveys, not double-blind controlled trials, and due to the researchers' perception bias against conventional technology, whether cardiac arrest is related to folic acid needs further confirmation.
[0014] At present, most of the international medical community recognizes that women preparing for pregnancy can help reduce the risk of developing congenital heart disease by taking folic acid supplements, and it is also common knowledge in China that pregnant women should take folic acid supplements, but the incidence of congenital heart disease is still increasing. After statistical analysis of the incidence of congenital heart disease in countries around the world, especially data on atrial septal defect (ASD) (see Figure 1 in the instruction manual), it was surprisingly found that since 1998, the birth rate of ASD in North America and Asia has increased significantly, while it has declined to a certain extent in Europe and South America [Liu Y, Chen S, Zuhlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019;48(2):455-463.]. It is worth noting that in 1998, the United States issued a requirement to add folic acid to staple foods such as cereals, flour, and bread, and Canada also issued a similar requirement. There is no mandatory requirement in Europe, and the dependency on folic acid supplements is low in European countries. According to the European Birth Defects Monitoring Report published in 2009, the dependency on folic acid supplements is 5% to 40%.
[0015] Since 1980, the birth rate of ASD in China has increased rapidly. After conducting research, the inventors found that the incidence rate of CHD in urban population is much higher than that of rural population in China, and has a tendency to gradually expand. According to estimates by the World Health Organization (WHO), the incidence rate of congenital defects in low-income countries in the world is 6.42%, in middle-income countries it is 5.57%, and in high-income developed countries it is 4.72%. China's economic development is rapid, and the standard of living and medical health care level are rapidly improving, especially in developed cities in the east, such as Shanghai and the entire Sunan area, have reached the level of developed countries, but the birth defect rate of infants is not controlled at the corresponding level. Conversely, the urban population has a higher birth defect rate than the rural population, and as can be seen from the literature report, the incidence rate of CHD in China has increased significantly in recent years, increasing slowly from 1980 to 2004, and then increasing significantly from 2005 to 2019. According to the research report [Zhao L, Chen L, Yang T, et al. Birth prevalence of congenital heart disease in China, 1980-2019: a systematic review and meta-analysis of 617 studies. Eur J Epidemiol. 2020;35(7):631-642.], the birth rate of congenital heart disease in China rose from 0.201 per 1,000 infants in 1980-1984 to 4.905 per 1,000 infants in 2015-2019. It should be noted that in China, the birth rate of ASD increased significantly over time from 1980 to 2019, from about 0.25‰ in 1980 to 0.5‰ in 2000, and rose rapidly to 3‰ after 2000, with ASD accounting for almost half of congenital heart disease.
[0016] During this period, folic acid supplementation for pregnant women was started throughout China, and some regions implemented a free folic acid policy. The incidence of neural tube defects was significantly reduced by folic acid supplementation, but the incidence of pre-existing heart disease was significantly increased. Based on epidemiological statistics and the local folic acid use situation, the inventors carefully suspected whether folic acid supplementation had a certain correlation with the increase in the incidence of pre-existing heart disease, and confirmed in the research disclosed in this invention that folic acid (unmetabolized folic acid) can improve the incidence of pre-existing heart disease.
[0017] Formaldehyde is a colorless, irritating gas that is easily soluble in water and ethanol and is widely used in human industrial production, including chemical industry, wood industry, textile industry, and preservative construction. As the demand for health increases, the harm of formaldehyde in the environment is increasingly emphasized. Formaldehyde is inevitably generated during the house decoration process, and it is difficult to completely remove this formaldehyde. Therefore, the content of formaldehyde in new houses is often higher than the safe value, and the risk of miscarriage and fetal health damage for pregnant women is also increasing. In the course of research into heart disease, the inventors unexpectedly found that 5-methyltetrahydrofolic acid can save zebrafish embryos affected by formaldehyde, and that high concentrations of 5-methyltetrahydrofolic acid are non-toxic and non-teratogenic. Summary of the Invention
[0018] The present invention is based on animal experiments, and as a result of research, it was found that taking folic acid during pregnancy can cause teratogenicity in the embryo due to unmetabolized folic acid, and long-term or excessive supplementation of folic acid can cause the occurrence of congenital heart disease. However, 5-methyltetrahydrofolic acid is not teratogenic, and has the effect of preventing the occurrence of congenital heart disease when taken during pregnancy.
[0019] The present invention provides a drug or health food containing 5-methyltetrahydrofolic acid, which is used for preventing congenital heart disease in newborns by pregnant women.
[0020] The drug or health food of the present invention is used for pregnant women to prevent the occurrence of congenital heart disease in newborns.
[0021] According to the drug or health functional food of the present invention, the congenital heart disease is the most common congenital malformation, and refers to an abnormal anatomical structure caused by impaired or malformed formation of the heart and great blood vessels during embryonic development, or the inability of passages that should close automatically after birth to close.
[0022] According to the drug or health food of the present invention, the congenital heart disease includes three subgroups of diseases. 1) Congenital aortic anomalies, including patent ductus arteriosus, aortic stenosis, pulmonary stenosis, pulmonary atresia, and other congenital aortic anomalies; 2) Congenital cardiac septal anomalies, including atrioventricular septal defects (AVSDs), ventricular septal defects (VSDs), atrial septal defects (ASDs), tetralogy of Fallot, aortopulmonary septal defect, and other congenital septal anomalies; 3) Other congenital heart diseases, including congenital coaptation of the heart chambers, and congenital aortic and mitral valve anomalies.
[0023] According to the drug or health food of the present invention, the drug or health food contains an effective amount of 5-methyltetrahydrofolic acid, and further contains pharma-ceutically acceptable auxiliary materials or supplements.
[0024] According to the drug or health functional food of the present invention, it may be in various dosage forms known in the art. For example, it may be an enteral dosage form such as oral administration, sublingual administration or rectal administration. For example, the oral dosage form may be a tablet, capsule, oral liquid, drop pill, pill, powder, granule. For example, the injection dosage form may be a powder injection, a solution, an emulsion, a suspension.
[0025] According to the drug or health food of the present invention, the amount of 5-methyltetrahydrofolic acid used is 0.05 to 50 mg / day, preferably 0.2 to 0.8 mg / day.
[0026] Another aspect of the present invention provides a drug or health food for preventing miscarriage in pregnant women caused by formaldehyde and protecting the fetus.
[0027] The above-mentioned medicines or health foods for preventing miscarriage in pregnant women caused by formaldehyde and protecting the fetus can prevent miscarriage in pregnant women caused by long-term exposure to a formaldehyde environment.
[0028] The above-mentioned medicine or health food for preventing miscarriage in pregnant women caused by formaldehyde and protecting the fetus can be used to treat symptoms of threatened miscarriage in pregnant women caused by formaldehyde.
[0029] According to the drug or health functional food for preventing miscarriage in pregnant women caused by formaldehyde and protecting fetuses described in the present invention, it may be in various dosage forms known in the art. For example, it may be an enteral dosage form such as oral administration, sublingual administration or rectal administration. For example, the oral dosage form may be a tablet, capsule, oral liquid, drop pill, pill, powder, or granule. For example, the injection dosage form may be a powder injection, solution, emulsion, or suspension.
[0030] According to the drug or health functional food for preventing miscarriage in pregnant women caused by formaldehyde and protecting the fetus described in the present invention, the amount of 5-methyltetrahydrofolic acid used is 0.05 to 50 mg / day, preferably 0.2 to 0.8 mg / day, and the therapeutic dose for threatened miscarriage is 0.8 to 200 mg / day, preferably 20 mg / day.
[0031] Obviously, according to the above content of the present invention, various other forms of modifications, substitutions or alterations can be made according to common technical knowledge and common means in this field without departing from the above basic technical idea of this embodiment.
[0032] It is especially worth noting that due to differences in laws and regulations of different countries, for example, dietary supplements in the United States can emphasize related functions (FDA recognizes that dietary supplements can explain the relationship between food or dietary components and health conditions or disease risk reduction), so 5-methyltetrahydrofolic acid can not only be used in the preparation of drugs or health functional foods for preventing congenital heart disease, miscarriage and stillbirth, but also in the preparation of supplements and special medical purpose preparations with the above functions. Examples include multivitamin tablets containing 5-methyltetrahydrofolic acid, infant formula, etc.
[0033] The use of calcium 5-methyltetrahydrofolate in the preparation of a drug or health food for preventing fetal cardiac malformations.
[0034] The cardiac malformation is preferably induced by ethanol, lead nitrate, or aristolochic acid. The 5-methyltetrahydrofolic acid includes 5-methyltetrahydrofolic acid or a pharma- ceutically acceptable salt thereof.
[0035] The 5-methyltetrahydrofolic acid is selected from 5-methyl-(6S)tetrahydrofolic acid, 5-methyl-(6R)tetrahydrofolic acid, or 5-methyl(6R,S)tetrahydrofolic acid, i.e. includes optical isomers of 5-methyltetrahydrofolic acid, mixtures of optical isomers, in particular the pure naturally occurring optical isomer.
[0036] The pharma- ceutically acceptable salts include the corresponding acid addition salts formed by conversion of a basic group in 5-methyltetrahydrofolic acid, and the corresponding base addition salts formed by conversion of an acidic group in 5-methyltetrahydrofolic acid, and are preferably ammonium salts with hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, sodium, potassium, magnesium, calcium, substituted ammonium salts, or salts formed with arginine or lysine.
[0037] The use of 5-methyltetrahydrofolic acid in the preparation of drugs for the prevention of congenital heart diseases caused by heavy metals, alcohol and drugs. [Brief description of the drawings]
[0038] [Figure 1] Birth rates of different subtypes of congenital heart disease in China from 1980 to 2019, and birth rates of atrial septal defect in different regions of the world from 1970 to 2017. [Diagram 2] 1A shows the effect of 10 mM L-5-MTHF-Ca on the survival rate of zebrafish embryos in Experimental Example 1, and FIG. 1B shows the effect of L-5-MTHF-Ca on the development of zebrafish embryos in Experimental Example 1. [Diagram 3] 1 shows the effects of L-5-MTHF-Ca on the heart rate and body length of zebrafish at 48 hpf and 72 hpf in Experimental Example 1. [Figure 4] a) Effects of MTX and MTX+L-5-MTHF-Ca on the survival rate of zebrafish embryos in Experimental Example 2, where ns indicates no significant difference compared to the control and **** indicates p<0.005. b) Effects of the MTX model group and the L-5-MTHF-Ca rescue group on the development of zebrafish embryos. [Diagram 5] Effects of MTX and MTX+L-5-MTHF-Ca on the pericardial edema rate, heart rate, and body length of zebrafish embryos in Experimental Example 2. ns indicates no significant difference compared to the control, **** indicates p<0.005, *** indicates p<0.01, and * indicates p<0.1. [Figure 6] 1A shows the effect of different concentrations of folic acid on the survival rate of zebrafish embryos in Experimental Example 3. FIG. 1B shows the effect of different concentrations of folic acid on the heart rate of zebrafish embryos. [Figure 7] 13 is the effect of different concentrations of folic acid on the morphology of zebrafish embryos at 8 hpf and 24 hpf in Experiment 3. [Figure 8]In Experiment 3, the effects of 10 mM L-5-MTHF-Ca, 8 mM FA, 6 mM FA, and 4 mM FA on the zebrafish heart at 72 hpf. The left figure shows the development of the heart embryos at 72 hpf with different concentrations of folic acid, and microscopic observation revealed pericardial edema malformation / atrial and ventricular elongation, and impaired development of the subintestinal plexus vascular system. The right figure shows the effect of folic acid on the body length of zebrafish at 72 hpf. [Figure 9] Experimental Example 4: Effect of folic acid on the expression of different transcription factors in zebrafish embryos. [Figure 10] Experimental Example 4: Effect of 5-methyltetrahydrofolate on the expression of different transcription factors in zebrafish embryos. [Figure 11] 4A shows the effects of FA and FA+L-5-MTHF-Ca on the survival rate of zebrafish embryos in Experimental Example 5. FIG. 4B shows the effects of FA and FA+L-5-MTHF-Ca on the development of zebrafish embryos in Experimental Example 5. [Figure 12] 1 shows the pericardial edema rate and heart rate of 48 hpf zebrafish embryos, and the body length of 72 hpf zebrafish embryos in Experimental Example 5. [Figure 13] a) Effects of formaldehyde and formaldehyde + L-5-MTHF-Ca on the survival rate of zebrafish embryos in Experimental Example 6. b) Effects of formaldehyde and formaldehyde + L-5-MTHF-Ca on the development of zebrafish embryos. [Figure 14] 4. Effects of heart rate of 48 hpf zebrafish embryos and body length of 72 hpf zebrafish embryos in Experimental Example 6. [Figure 15] a) The effect of low homocysteine on myocardial trabeculae in Experiment 7. b) Low homocysteine causes a small amount of lymphocyte infiltration into the myocardial cell gap. c) Low homocysteine causes a light pink serous substance to be seen in the right ventricle. d) High homocysteine causes red staining of muscle cytoplasm in fetal mice. [Figure 16] In Experiment 7, the effect of high homocysteine on the fetal mouse heart. [Figure 17] FIG. 1 is a cross-sectional view of the heart of a normal rat in Experimental Example 8. [Figure 18] In Experiment 8, the effect of high doses (36.44 mg / kg) of folic acid on the hearts of fetal mice. [Figure 19] In Experiment 8, the effect of high doses (18.22 mg / kg) of folic acid on the fetal mouse heart. [Figure 20] In Experiment 8, the effect of high doses (9.11 mg / kg) of folic acid on the hearts of fetal mice. [Figure 21] This is a representative heart section image of a fetal mouse in the 2.2775 mg / kg folic acid group in Experimental Example 9. [Figure 22] This is a representative heart section image of a fetal mouse in the 0.911 mg / kg folic acid group in Experimental Example 9. [Figure 23] These are echocardiograms of 6-day-old neonatal mice in Experimental Example 10, showing the control (A), low-dose folic acid group (B), high-dose folic acid group (C), low-dose methyltetrahydrofolic acid group (D), and high-dose methylenetetrahydrofolic acid group (E). [Figure 24] These are echocardiogram data from 6-day-old neonatal mice in Experimental Example 10, showing the control (A), low-dose folic acid group (B), high-dose folic acid group (C), low-dose methyltetrahydrofolic acid group (D), and high-dose methylenetetrahydrofolic acid group (E). [Diagram 25] 1 shows representative cardiac sections from fetal mice of each group in Experimental Example 10. [Figure 26] a) is a survival rate test of zebrafish embryos by Pb(NO3)2 and Pb(NO3)2 + L-5-MTHF-Ca in Experimental Example 11. b) is an effect of Pb(NO3)2 model group and L-5-MTHF-Ca rescue group on the development of zebrafish embryos. [Figure 27] 13 shows the heart rate of 48 hpf zebrafish embryos and the body length and malformation rate of 72 hpf zebrafish embryos affected by lead acetate and methyltetrahydrofolate in Experiment 11. [Figure 28]A shows the survival rate of zebrafish treated with ethanol and ethanol+L-5-MTHF-Ca in Experimental Example 11. B shows the effects of ethanol and L-5-MTHF-Ca on the development of zebrafish. [Figure 29] 13 shows the heart rate, body length and malformation rate of zebrafish embryos affected by ethanol and methyltetrahydrofolate in Experimental Example 11. [Diagram 30] 1 shows a test of the survival rate of zebrafish embryos in the presence of aristolochic acid A and aristolochic acid A+L-5-MTHF-Ca in Experimental Example 11. [Diagram 31] 13 shows the effects of the aristolochic acid A model group and the L-5-MTHF-Ca + aristolochic acid A group on the development of zebrafish embryos in Experimental Example 11. [Diagram 32] 1 shows the pericardial edema rate, heart rate and body length of zebrafish embryos at 48 hpf and 72 hpf, respectively, affected by aristolochic acid A and 5-methyltetrahydrofolic acid in Experimental Example 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0039] In the present invention, the term "5-methyltetrahydrofolic acid" includes 5-methyl-(6S)tetrahydrofolic acid, 5-methyl-(6R)tetrahydrofolic acid, 5-methyl(6R,S)tetrahydrofolic acid, i.e., optical isomers of 5-methyltetrahydrofolic acid, in particular the pure naturally occurring optical isomer, mixtures of optical isomers, e.g. racemic mixtures, and physiologically acceptable salts thereof. Among them, 5-(methyl)-(6S)tetrahydrofolic acid is particularly preferred.
[0040] The physiologically acceptable salts refer to the corresponding acid addition salts converted from the basic groups in 5-methyltetrahydrofolic acid, and the acids may be inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, or organic acids such as formic acid, acetic acid, propionic acid, diethylacetic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, or nicotinic acid.
[0041] The physiologically acceptable salts may also refer to the corresponding base addition salts converted from the acidic group in 5-methyltetrahydrofolic acid, suitable salts being, for example, ammonium salts with sodium, potassium, magnesium, calcium, substituted ammonium salts, and salts formed with arginine and lysine. The folic acid described in the present invention means pteroylglutamic acid, which is a synthetic folic acid, also known as vitamin B9 and vitamin M, and its English name is folic acid. According to a research paper [Baohong M, Jie Q, Nan Z, et al. Maternal folic acid supplementation and dietary folate intake and congenital heart defects [J]. PLOS ONE, 2017, 12(11):e0187996-.], pregnant women who took 266.5 μg or more of folic acid daily in the month before pregnancy had a higher incidence of atrioventricular septal defect (ASD) in newborns than pregnant women who took 115.97 to 265.5 μg of folic acid daily, but the author ignores this phenomenon and still believes that folic acid supplementation is advantageous for reducing the incidence of congenital heart disease in newborns. The phenomenon that 265.5 μg / day is still below the intake recommended by the United Nations has not been further examined by the author. The argument that folic acid supplementation increases the incidence of congenital heart disease in newborns is a subversive argument and has not been found. The main reason may be that the absolute value of the incidence of newborn defects is originally very low. Congenital heart disease, which is the main type of congenital defect, is less than 5‰, and it is unrealistic to include tens of thousands of pregnant women to verify directly by clinical control. In previous research reports, statistical analysis of medical records could not control the effects of the folic acid level and diet of the included cases themselves, making it difficult to exclude their effects.
[0042] When pregnant women are supplemented with folic acid, unmetabolized folic acid may be present in the blood circulation. In a study on folic acid supplementation in pregnant women [Obeid R, Kasoha M, Kirsch SH. Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood[J]. American Journal of Clinical Nutrition, 2010, 92(6):1416-1422.], American scholars reported that 0.19 nmol / L of unmetabolized folic acid was detected in the serum of 25 pregnant women who supplemented with folic acid during pregnancy, and the folic acid concentration in umbilical cord blood was as high as 0.27 nmol / L, suggesting that unmetabolized folic acid may accumulate in higher concentrations in the fetus than in the mother.
[0043] The inventors of the present invention have discovered that folic acid exhibits teratogenic effects on zebrafish embryos. Folic acid intervention induces pericardial edema, slow heart rate, and shortened body length in zebrafish embryos. Microscopic observation has revealed that folic acid induces pericardial edema, pigmentation disorders, and intersegmental vascular hypoplasia in zebrafish. As can be seen from this, folic acid can also exhibit teratogenic effects on human embryo development. The crucial period for human embryo development and heart formation is before 8 weeks, and early fetal cardiac circulation is formed at 6 to 8 weeks of pregnancy. Folic acid exhibits teratogenic effects on both vascular development and pericardial development, causing cardiovascular abnormalities and diaphragmatic malformations in newborns, resulting in congenital heart disease.
[0044] The inventors further demonstrated that 5-methyltetrahydrofolic acid did not exhibit teratogenic effects on zebrafish embryos, and there was no difference between the normal embryo group and the 5-methyltetrahydrofolic acid intervention group. With 5-methyltetrahydrofolic acid intervention, the cardiac outline of zebrafish embryos was normal, and the development of the subintestinal plexus blood vessels was normal.
[0045] In one embodiment, the inventors collected zebrafish embryos at different times (24h, 48h) after folic acid intervention, and used quantitative PCR technology to detect the expression of different transcription factors in zebrafish embryos. As a result, the expression of transcription factors NKx2.5, amhc, vmhc, hand2, has2, mef2a, mef2c, bmp2b, ephrinB2, and ephB4 in zebrafish embryos was affected by folic acid intervention, and NKx2.5, hand2, has2, mef2c, and ephB4 have all been proven to be important transcription factors in the cardiac development process, and the inventors found that folic acid had a significant effect on mef2c, bmp2b, vmhc, has2, and ephb4.
[0046] The human mef2 family includes four members, mef2a, mef2b, mef2c and mef2d, of which mef2b and mef2c are first activated in the heart embryo on day 7 of the embryo, and mef2c is a key member that forms the mesoderm cells of the primitive heart tube during embryonic development. Loss of mef2c causes serious cardiac structural abnormalities, especially atrial septal defect or ventricular septal defect [Qiao XH,Wang F,Zhang XL,et al.MEF 2 C loss-of-function mutation contributes to congenital heart defects.IntJ Med Sci.2017;14(11):1143-153.]. Folic acid affects the expression of mef2c, which may also be a possible cause of the increased birth rate of ASD. Hyaluronan is also highly expressed during cardiac development and plays an important role in cell migration and transformation. It has been reported that expression of the human has gene regulates hyaluronan synthesis, and that mutations in the has2 gene may affect cardiac septum formation in embryos [Zhu X, Deng X, Huang G, et al. A novel mutation of Hyaluronan synthase 2 gene in Chinese children with ventricular septal defect. PLoS One. 2014;9(2):e87437.].
[0047] The inventors simultaneously collected zebrafish embryos at different times (24h, 48h) after 5-methyltetrahydrofolate intervention and detected the expression of different transcription factors in the zebrafish embryos using quantitative PCR technology. As a result, no effect of 5-methyltetrahydrofolate intervention on the expression of transcription factors was observed, and there was no difference in the expression of transcription factors compared to the normal control.
[0048] In one embodiment, the inventors found that 5-methyltetrahydrofolic acid cannot rescue malformations in zebrafish embryos caused by synthetic folic acid-induced hydropericardium, but can rescue the malformations of zebrafish, such as slow heart rate and shortened body length.
[0049] In order to further confirm the effect of folic acid on embryonic heart development, in Example 9, the effect of different doses of folic acid on the hearts of fetal mice was examined. As a result, at a certain dose, the ventricular walls of the hearts of fetal mice were too thin, and ventricular septal defects were individually observed. In Example 10, when the fetuses of mother mice that had ingested folic acid and mother mice that had ingested 5-methyltetrahydrofolic acid were compared, the incidence of aortic heart disease in mother mice in the low-dose folic acid group was 5.95%, while the incidence of aortic heart disease in mother mice in the high-dose folic acid group was 22.2%, and the fetuses of the 5-methyltetrahydrofolic acid group were free of aortic heart disease, further proving the effect of folic acid on embryonic heart development.
[0050] Furthermore, the inventors have found that 5-methyltetrahydrofolic acid has the effect of preventing embryonic cardiac malformations induced by alcohol, lead nitrate, and aristolochic acid A. The above substances are shown to cause neonatal cardiac malformations due to different environmental factors, such as alcoholism, heavy metals, and drugs, respectively, so 5-methyltetrahydrofolic acid has a wide range of effects in preventing the occurrence of pre-existing cardiac diseases.
[0051] In one embodiment of the present invention, the inventors have found that 5-methyltetrahydrofolic acid can prevent cardiac malformations caused by folate deficiency.
[0052] The drug or health food of the present invention contains 0.1mg-200mg of 5-methyltetrahydrofolic acid per dose, and when it is a prophylactic drug, it is preferable to use 0.1mg-1mg of 5-methyltetrahydrofolic acid per dose. The specific dose depends on various factors such as the patient's age, body weight, administration time and route, and individual condition, and the optimal dose is preferably 0.1-1mg / day, for example 0.8mg / day.
[0053] In the present invention, the drug or health functional food comprises various carriers, excipients and / or auxiliary functional agents such as water, oil, benzyl alcohol, polyethylene glycol, glycerin triacetate, gelatin, lecithin, cyclodextrin, sugars such as lactobiose or starch, magnesium stearate, talc, silica gel or cellulose. The auxiliary functional agent is, for example, a stabilizer, an antioxidant, a buffer, an antibacterial agent, etc. In one embodiment of the present invention, the excipient or carrier is microcrystalline cellulose, or a combination of microcrystalline cellulose and cross-linked sodium carboxymethylcellulose, or fine powder silica gel.
[0054] The present invention is the first to discover that unmetabolized folic acid entering the blood circulation after pregnant women take folic acid causes congenital heart disease. Folic acid is a synthetic oxidized form that is not found in natural foods and cannot be used by the human body unless it is converted to tetrahydrofolic acid by human dihydrofolate reductase (DHFR). However, this process is slow in the human body, and unmetabolized folic acid can be detected in the plasma several hours after taking 200 μg or more of folic acid, which is also a possible reason why folic acid is confused with the clinical statistical results of congenital heart disease and the conclusions are inconsistent. The present invention also explains the reason why previous studies are contradictory to each other, and since no nutritional and folic acid supplementation policies were issued in the 1980s and 1990s, it is possible that pregnant women's own folic acid levels are relatively low, making it easier to draw positive conclusions. As more and more foods containing folic acid for nutritional supplementation become available, it is difficult to recognize the correlation between folic acid and congenital heart disease at high doses of folic acid. In addition, before 2000, the incidence of septal defects was very low, so it was discovered that statistically there may be a certain correlation between folic acid and this subtype, but researchers ignored this phenomenon or considered it a statistical deviation due to cognitive deficiencies and prejudices.
[0055] Folic acid has been used on a large scale to prevent congenital malformations in fetuses. However, the present invention analyzed epidemiological data and the folic acid supplementation situation in the relevant region, and obtained contradictory results that the incidence of congenital heart disease increases after folic acid supplementation. It carefully proposed that folic acid supplementation increases the incidence of congenital heart disease, and the results of animal experiments and epigenetics of the present invention also substantiate this conclusion.
[0056] The present invention has also discovered that 5-methyltetrahydrofolic acid has the effect of preventing congenital heart disease, the preventive dose for 5-methyltetrahydrofolic acid may be 1 mg or more, and has no teratogenic effect even when used in high doses compared to synthetic folic acid, and can prevent congenital defects at high doses, which is a significant advancement, especially in the prevention of congenital heart disease in newborns. EXAMPLES
[0057] Example 1 0.4 g of 5-methyltetrahydrofolic acid calcium salt was mixed with 700 g of microcrystalline cellulose, and the mixture was dry granulated and then filled into 1000 capsules to prepare a capsule formulation containing 0.4 mg of 5-methyltetrahydrofolic acid calcium per capsule.
[0058] Example 2 200 g of finely powdered silica gel was added to 1 g of 5-methyltetrahydrofolic acid calcium salt, mixed uniformly, and then pressed into tablets using a tablet press to prepare tablets each containing 2 mg of 5-methyltetrahydrofolic acid.
[0059] Experimental Example 1 Effects of calcium 5-methyltetrahydrofolate (L-5-MTHF-Ca) on survival and cardiovascular development in zebrafish embryos Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertilized eggs twice a day. Three zebrafish, one female and two males, were placed in an egg-laying box the night before, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Ten fish per well (n=10) were cultured in a 24-well plate with 1mL of embryo culture medium added beforehand. Each group was tested three times. Zebrafish embryos were treated from 2h after fertilization (2hpf) until 72hpf. The number of deaths in each group was recorded at 8, 24, 48, and 72hpf. The embryos were not fed during the treatment period, and were promptly sorted when they died. The phenotype of malformations was observed, and the number of all abnormal zebrafish with malformations was recorded. Indicators such as survival rate, morphological defects, heart rate, and heart morphology were observed and evaluated using an SMZ745T inverted stereo microscope.
[0060] The test results are as follows: 10mM L-5-MTHF-Ca had no effect on embryo survival rate, and compared with the normal group, at 8hpf, the phenotypes of normal embryos and 10mM L-5-MTHF-Ca embryos were similar, and the covering was almost complete. At 24hpf, the normal embryos were similar to those of 10mM L-5-MTHF-Ca, with head and tail development, and the tail had a wobbling phenomenon. After 48hpf, the head and tail of each group were fully developed, whole body pigmentation was formed, the heart beat was obvious, the intersegmental vascular development was normal, and blood flowed throughout the body. At 72hpf, the external appearance of the heart of each group was normal, and the development of the subintestinal plexus vessels was normal (see Figure 2). We measured the heart rate of zebrafish embryos at 48 hpf and the body length of zebrafish embryos at 72 hpf and found that there was no difference in heart rate or body length between 10 mM L-5-MTHF-Ca and the control (see Figure 3).
[0061] Experimental Example 2 Effects of L-5-MTHF-Ca on cardiovascular development in methotrexate (MTX)-induced folate-deficient zebrafish embryos Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertile eggs twice a day. Three zebrafish, one female and two males, were placed in an egg-laying box the night before, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Zebrafish embryos were placed in 24-well plates at 6hpf, administered drugs, and cultured until 10hpf, when 1mL of 1.5mM MTX solution was added to 10 embryos per well, and then transferred to egg liquid and continued to be cultured until 72hpf. Embryos were immediately sorted out when they died. The phenotype of malformation was observed, the number of all abnormal zebrafish with malformations was recorded, and the malformation rate and rescue rate of each group were calculated. Indicators such as morphological defects, heart rate, and heart morphology were observed and evaluated using an SMZ745T inverted stereo microscope.
[0062] The results are as follows (see Figure 4). 1.5 mM MTX significantly reduced embryo survival rate (survival rate less than 0.1), while the group with 10 mM L-5-MTHF-Ca could rescue the effect of 1.5 mM MTX on embryo survival rate, and the difference from the control was not significant. Compared with the normal control, the phenotype of zebrafish embryos at different time points was evaluated, and neither 1.5 mM MTX nor 1.5 mM MTX + 10 mM L-5-MTHF-Ca showed obvious embryonic developmental delay. At 24 hpf, 1.5 mM MTX caused zebrafish growth retardation, with malformations such as microcephaly and short tail. At 48 hpf, 1.5 mM MTX caused zebrafish trunk bending, intersegmental vascular hypoplasia, and pericardial edema. At 72 hpf, 1.5 mM MTX reduced zebrafish body length and caused hypoplasia of the subintestinal plexus vasculature. Meanwhile, 10 mM L-5-MTHF-Ca could rescue the embryonic developmental malformations caused by 1.5 mM MTX. The malformation rate in the MTX group was 100%, but after the addition of L-5-MTHF-Ca, it was only 10%.
[0063] To further quantitatively evaluate the rescue effect of 10 mM L-5-MTHF-Ca against MTX, we evaluated the pericardial edema, 10s heart rate, and body length of zebrafish embryos at 48 hpf among groups at 72 hpf. As can be seen from Figure 5, 1.5 mM MTX caused pericardial edema, slow heart rate, and shortened body length in zebrafish, but the group with 10 mM L-5-MTHF-Ca rescued the malformation phenotypes of pericardial edema, slow heart rate, and shortened body length in zebrafish.
[0064] Experimental Example 3 Teratogenic effects of folic acid (FA) on zebrafish embryos Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertile eggs twice a day. Three zebrafish, one female and two males, were placed in an egg-laying box the night before, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Zebrafish embryos were placed in 24-well plates from 2 hpf, administered drugs and cultured, 5 per well (n=5), until 72 hpf. Each well was added 1 mL of 20 mM NaHCO3 solution, 1 mL of 10 mM FA solution (solvent was 20 mM NaHCO3), 1 mL of 8 mM FA solution (solvent was 20 mM NaHCO3), 1 mL of 6 mM FA solution (solvent was 20 mM NaHCO3), 1 mL of 4 mM FA solution (solvent was 20 mM NaHCO3), 1 mL of 2 mM FA (solvent was 20 mM NaHCO3), and 1 mL of 10 mM L-5-MTHF-Ca (solvent was 20 mM NaHCO3). Embryos were sorted out immediately after death. Each group was repeated three times. Embryos were sorted out immediately after death. The phenotype of malformation was observed, the number of all abnormal zebrafish with malformations was recorded, and the malformation rate and rescue rate of each group were calculated. Indicators such as morphological defects, heart rate, and heart morphology were observed and evaluated using an SMZ745T inverted stereo microscope.
[0065] The results showed that 20 mM NaHCO3 did not affect zebrafish survival rate, and 10 mM L-5-MTHF-Ca did not affect zebrafish survival rate, all FA groups had low embryo survival rate, and zebrafish embryo mortality rate increased continuously with increasing dose (see Figure 6).Folic acid also affected embryo heart rate, especially at 48 hpf, with the greatest effect.Folic acid also affected zebrafish embryo body length, especially at 72 hpf, 8 mM folic acid significantly shortened embryo body length.
[0066] Compared with the normal control, the phenotypes of zebrafish embryos of each control at different time points were evaluated, and it was found that at 8 hpf, the normal control, L-5-MTHF-Ca group, NaHCO3 group, and 2 mM FA were all completely covered, while the zebrafish embryos of other concentrations of folic acid test groups all showed the phenomenon of incomplete coverage, and at 24 hpf, folic acid caused developmental malformations of the embryo's head and tail (see Figure 7). At 72 hpf, the normal zebrafish, L-5-MTHF-Ca group, NaHCO3 group, and 2 mM FA had normal embryonic heart shape and normal development of the subintestinal plexus vessels, but the 4 mM or higher FA group showed pericardial edema malformations, atrial and ventricular elongation, and impaired development of the subintestinal plexus vessels in the zebrafish embryos (see Figure 8).
[0067] Experimental Example 4 Effect of folic acid (FA) on the expression of different transcription factors during zebrafish embryo development To investigate the effect of folic acid on the epigenetics of zebrafish embryos during their development, zebrafish embryos at different developmental stages were collected and detected. Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertile eggs twice a day. Three zebrafish, one female and two males, were placed in an egg-laying box the night before, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Zebrafish embryos were placed in 24-well plates from 2 hpf, administered drugs, and cultured, 10 per well (n=10), and each well was added with 1 mL of 8 mM FA solution (solvent was 20 mM NaHCO3) and 1 mL of 8 mM L-5-MTHF-Ca (solvent was 20 mM NaHCO3 and 6S-5-methyltetrahydrofolate calcium), respectively, and fixed overnight in 4% paraformaldehyde solution at 24 h and 48 hpf, respectively, and stored in methanol solution at -20 °C until use. Zebrafish embryos were administered drugs from 2 hpf, and 10 zebrafish with clear phenotypes were collected every 24 h, and RNA was extracted from each group of zebrafish with Trizol according to the instructions, and embryos at two time points, 24 and 48 hpf, were extracted for the next experiment.
[0068] This qRT-PCR experiment used SYBR Green dye, a fluorescent dye. qRT-PCR was performed according to the instructions of the SYBR Green qPCR Master Mix kit, and finally detected by ABI (HT 7900) PCR meter. The gene primers used were synthesized by Kin Wei-chi Bioscience and Technology Co., Ltd., and the specific information is shown in Table 1. The expression level of β-actin was used as the internal reference, and the relative expression levels of other genes were calculated by the ΔΔCt method.
[0069] [Table 1]
[0070] As a result, zebrafish eggs formed a complete heart 48 h after fertilization, consisting of an atrium and a ventricle, with a valve between the atrium and the ventricle. Under the action of various signal molecules, cardiomyogenic genes in heart-forming cells, including Nkx-2 family genes and Mef2 family genes, were expressed. Folic acid inhibited the expression of various genes, and compared with the normal control, the expression of various genes was affected to different degrees (see Figure 9), while 5-methyltetrahydrofolic acid (6S-5-methyltetrahydrofolate calcium) showed no difference from the normal control (see Figure 10). Folic acid deficiency is thought to be involved in the formation of cardiomegaly, but folic acid itself was also involved in the formation of cardiomegaly. Folic acid increased the expression of mef2c gene at 24 hpf, but decreased the expression of bmp2b gene, and at 48 hpf, it suppressed the expression of has2, mef2c, and ephb4 genes, but increased the expression of vmhc. Mef2c is a key member that forms the germ layer cells of the primitive heart tube during embryonic development, and has2 also affects the formation of the embryonic cardiac septum, which may also be a possible reason for the significant increase in the birth rate of ASD.
[0071] Experimental Example 5 Rescue of the effects of FA on malformation, viability, heart rate, and body length in zebrafish embryos by L-5-MTHF-Ca To investigate whether 5-methyltetrahydrofolic acid can reduce FA-induced teratogenicity, the following experiment was performed. Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than 1 year old, with the pH value of the rearing water body being 7±0.2, the temperature being about 28°C, the light and dark time ratio being 14h:10h, and they were fed with fertile eggs twice a day. On the night before, three zebrafish, one female and two males, were placed in an egg-laying box, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Zebrafish embryos were placed in 24-well plates from 2hpf, administered drugs, and cultured, and 1mL of 6mM FA solution (solvent was 20mM NaHCO3) was added to 10 embryos per well until 72hpf. When the embryos died, they were immediately sorted out. The test of each group was repeated three times. 6 mM FA was selected to make the model, and at the same time, rescue test was performed with 10 mM L-5-MTHF-Ca, and solvent control was set with 20 mM NaHCO3. The malformation phenotype was observed, and the number of all abnormal zebrafish with malformation was recorded, and the malformation rate and rescue rate of each group were calculated. Indicators such as morphological defects, heart rate, and heart morphology were observed and evaluated under an SMZ745T inverted stereo microscope.
[0072] The results were as follows. 6mM FA was selected to make a model, and at the same time, a rescue test was performed with 10mM L-5-MTHF-Ca, and a solvent control of 20mM NaHCO3 was set. It was found that 20mM NaHCO3 had no effect on zebrafish survival rate, and 6mM FA caused a very low embryo survival rate, but the group with 10mM L-5-MTHF-Ca could rescue the effect of 6mM FA on embryo survival rate. Compared with the normal control, the phenotype of zebrafish embryos at different time points was evaluated (see Figure 11), and at 8hpf, normal embryos were almost completely covered, and the development of zebrafish embryos was delayed in both 6mM FA and 6mM FA + 10mM L-5-MTHF-Ca groups. At 24hpf, normal zebrafish embryos had developed heads and tails, and the tails had a wagging phenomenon. 6 mM FA caused microcephaly and brachycae in zebrafish, but 6 mM FA + 10 mM L-5-MTHF-Ca alleviated these malformations. At 48 hpf, both 6 mM FA and 6 mM FA + 10 mM L-5-MTHF-Ca caused pericardial edema, pigmentation defects, and intersegmental vascular malformation in zebrafish. At 72 hpf, both 6 mM FA and 6 mM FA + 10 mM L-5-MTHF-Ca groups caused subintestinal plexus vascular malformation in zebrafish. However, 20 mM NaHCO3 (vehicle control) showed phenotypes similar to those of normal groups at each time point.
[0073] To further quantitatively evaluate the rescue effect of 10 mM L-5-MTHF-Ca against 6 mM FA, the pericardial edema of zebrafish embryos at 48 hpf, 10s heart rate, and body length of zebrafish among each group at 72 hpf were evaluated. As can be seen from Figure 12, 6 mM FA caused severe pericardial edema in zebrafish, and 10 mM L-5-MTHF-Ca could not rescue the malformation of pericardial edema. 6 mM FA caused slow heart rate and short body length in zebrafish, but the group with 10 mM L-5-MTHF-Ca could rescue the malformation phenotype of slow heart rate and short body length in zebrafish. 20 mM NaHCO3 (solvent control) had no effect on the heart, heart rate, or body length of zebrafish embryos.
[0074] In conclusion, 10 mM L-5-MTHF-Ca can rescue the reduced viability, slow heart rate, and shortened body length of zebrafish embryos induced by 6 mM FA, but cannot rescue hydropericardium or pigmentation disorders.
[0075] Experimental Example 6 Rescue of the effects of formaldehyde (HCHO) on zebrafish embryo viability by L-5-MTHF-Ca Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water body was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertile eggs twice a day. Three zebrafish, one female and two males, were placed in an egg-laying box the night before, and the eggs were collected the next morning. The fish eggs were placed in embryo culture medium (containing 0.2g / L sea salt) and cultured at 28°C. Zebrafish embryos were placed in 24-well plates from 2hpf and cultured with drugs (10mM L-5-MTHF-Ca), and 1mL of 30mM HCHO solution was added per well with 10 embryos per well. When the embryos died, they were immediately sorted. The experiment for each group was repeated three times. The phenotype of malformation was observed, the number of all abnormal zebrafish with malformations was recorded, and the malformation rate and rescue rate of each group were calculated. Indicators such as morphological defects, heart rate, and heart morphology were observed and evaluated using an SMZ745T inverted stereo microscope.
[0076] The results were as follows. 30 mM HCHO was selected to make a model, and 10 mM L-5-MTHF-Ca was used for rescue at the same time. 30 mM HCHO significantly reduced the embryo survival rate, but the group with 10 mM L-5-MTHF-Ca could rescue the effect of 30 mM HCHO on embryo survival rate. The phenotype of zebrafish embryos at different time points was evaluated compared with the control (see Figure 13). At 8 hpf, normal embryos were almost completely covered, but both 30 mM HCHO and 30 mM HCHO + 10 mM L-5-MTHF-Ca groups delayed the development of zebrafish embryos. At 24 hpf, normal zebrafish embryos had developed heads and tails, and there was a wagging phenomenon in the tails, and 30 mM HCHO and 30 mM HCHO + 10 mM L-5-MTHF-Ca were similar to the phenotype of control zebrafish. At 48 hpf, zebrafish embryos were observed and photographed under bright field and fluorescent microscopes. The normal embryos and the 30 mM HCHO and 30 mM HCHO + 10 mM L-5-MTHF-Ca groups were similar, with fully developed head and tail, whole body pigmentation, obvious heart beating, normal intersegmental vascular development, and blood flow throughout the body. At 72 hpf, the normal embryos and the 30 mM HCHO and 30 mM HCHO + 10 mM L-5-MTHF-Ca groups had normal cardiac appearance and normal intestinal plexus vascular development.
[0077] To further quantitatively evaluate the rescue effect of 10 mM L-5-MTHF-Ca against 30 mM HCHO, we evaluated the pericardial edema of zebrafish embryos at 48 hpf, the 10s heart rate, and the body length of zebrafish among each group at 72 hpf. Figure 14 shows that 30 mM HCHO and 30 mM HCHO + 10 mM L-5-MTHF-Ca did not affect the pericardium, heart rate, or body length of zebrafish.
[0078] In conclusion, 30 mM HCHO caused zebrafish death but no malformations, and 10 mM L-5-MTHF-Ca could rescue the reduced viability of zebrafish embryos caused by 30 mM HCHO. These findings indicate that L-5-MTHF-Ca can rescue the high embryo mortality rate of pregnant women exposed to a formaldehyde environment for a long period of time.
[0079] Experimental Example 7 Effects of homocysteine on fetal mouse development To study the effect of homocysteine on the fetal heart, SD rats were selected, and male and female rats were placed in the same cage in a 1:1 ratio and mated overnight. The vaginal plug was examined the next morning, and the day when the vaginal plug was observed was considered as day 0 of pregnancy. The pregnant mice were raised alone. A 1% homocysteine solution (HCY) was used, and the injection amount was calculated with an injection volume of 1ml / 100g, and the dose was (100mg / kg / d). The pregnant mice were intraperitoneally injected once a day from the 7th day of pregnancy to the 17th day of pregnancy, and once on the 19th day of pregnancy, so that the liquid would not circulate after each injection. On the 20th day of pregnancy, the mice were anesthetized with chloral hydrate, and the fetuses were collected by Caesarean section. A high HCY model pregnant mouse was considered in the same manner as above, and the dose was (200mg / kg / d), and the remaining conditions were the same. The fetal mice were dissected to collect the hearts, sliced, and observed. The results were as follows. Low HCY caused the fetal mouse myocardial trabeculae to expand and the atria to become filled with red blood cells (see Figure 15a). A small amount of lymphocytes infiltrated the myocardial gap (see Figure 15b). A small amount of lymphocytes infiltrated the right myocardial gap (see Figure 15c). High HCY caused the fetal mouse myocardial cytoplasm to turn red, as indicated by the black arrow (see Figure 15d). The ventricles and atria became filled with red blood cells, and the myocardial trabeculae expanded (see Figure 16). The above experiments have shown that HCY affects the mouse heart, and it has been speculated that high levels of human homocysteine may similarly cause cardiac disease.
[0080] Experimental Example 8 Effects of high doses of folic acid on the mouse heart (preliminary experiment) Twenty-eight healthy adult male and female SD rats, weighing approximately 200-250 g and purchased from SPF (Beijing) Biotechnology Co., Ltd., were selected. After all animals were purchased, the animals' general physiological indicators, body weight, and feeding status were observed. They were allowed to adapt and housed for one week. They were fed standard pelleted food and had free access to water. They were illuminated with natural day and night light, and the room temperature was 18-26°C and the relative humidity was 40%-70%.
[0081] The 16 pregnant mice obtained were randomly divided into 4 groups, 4 mice per group, according to weight: normal group, high-dose folic acid group, medium-dose folic acid group, and low-dose folic acid group. The high-dose folic acid group was 36.44 mg / kg, the medium-dose folic acid group was 18.22 mg / kg, the low-dose folic acid group was 9.11 mg / kg, and the blank control group were administered intragastrically, and the administration route was 1 ml / 100 g solution. Except for the normal group, pure water was given to the other groups, which were administered from the second day after the groups were divided, once a day for 21 consecutive days, and all pregnant mice in each group were allowed to drink water freely. Seven days after administration to female mice, male and female rats were placed in the same cage in a 1:1 ratio and mated, and the vaginal plug was examined the next morning. The day when the vaginal plug was observed was considered to be day 0 of pregnancy. The pregnant mice were kept alone and continued to be administered for another 21 days, and the fetuses were collected by Caesarean section.
[0082] Routine histopathological paraffin samples were prepared, sliced serially (5um thick), and HE stained. Sample preparation: Routine histological samples, paraffin, were prepared by slicing, with one paraffin block per sample. Slicing: Each numbered sample was sliced into 20 pieces. When mounting was started from the slice, the paraffin block showed ventricular mounting sections, and an average of four consecutive tissue points were mounted per slide. HE staining: Each sample was placed on 20 slides, and one was taken every other slide, for a total of 10 slides HE stained. Observation analysis: Leica panoramic images were taken and comparative analysis was performed. Fetal mouse hearts were dissected, sliced, and observed. The results were as follows:
[0083] In the normal group, the atria and ventricles were well differentiated, and the pericardium, endocardium and epicardium were intact. Longitudinal, oblique or transverse sections of myocardial fibers were observed simultaneously. The myocardial fibers were well arranged and regular, with a clear texture, and the myofibers branched and anastomosed into a network. The myocardial fibers were divided into different sizes of fiber bundles by loose connective tissue, and abundant blood vessels were found within the bundles. Densely developed myocardial trabeculae were formed in the atria and ventricles. The myocardial cells were normal, with orderly arranged cell nuclei, oval or spherical in shape, stained pale blue. A small number of round or elliptical blood cells stained red were present between the myocardial fibers. There were no obvious pathological changes. Depending on the development or cutting angle, some animals did not have an aortic structure connected to the ventricle (see Figure 17).
[0084] In the high-dose folic acid group, many animals shared the common features of delayed cardiac development (n=3), small heart volume, and thin heart walls (C9-1, C9-4, C9-5). Some animals had an absent interventricular septum (n=1) and a missing right ventricle (n=4), with solid muscle tissue or only a small cavity and almost no trabeculae. The inner wall of the left ventricular cavity was devoid of trabeculae or had only a few short, thick trabeculae. The left and right atria were nearly normal (C9-2, C9-3, C9-4, C9-5). The hearts of individual animals had different microscopic features, with obvious dilation of the left and right atrial cavities, similar size of the left and right ventricular cavities, sparse trabeculae in the left ventricle, and a smooth inner wall of the right ventricle with almost no trabeculae (C9-1). Depending on the development or the cutting angle, some animals did not have aortic structures (C9-3, C9-4) connected to the ventricle (see Figure 18).
[0085] In the medium-dose folic acid group, the ventricles and atria were differentiated and formed, and the pericardium, endocardium, and epicardium were intact. Longitudinal, oblique, and transverse sections of myocardial fibers were observed. Myocardial fibers were well developed, regularly arranged, and had a clear texture. No histiocyte degeneration or necrosis or inflammatory cell infiltration was observed. However, the ventricles and atria of individual animals were somewhat retarded in development (n=1), and the ventricles and ventricular volumes were small (D1-3). Some animals had ventricular cavity narrowing, delayed differentiation, smooth ventricular inner walls, and even ventricular defects (n=2), with almost no ventricular cavity, solid muscle tissue, short and sparse trabeculae (D1-3, D1-5), and rare trabeculae in the atria (D1-3) (see Figure 19).
[0086] In the low-dose folic acid group, the differentiation of the atria and ventricles was complete, the myocardial fibers were arranged in an orderly manner in bundles, the cross-sections of the myocardial fibers were distinct, the texture was clear, and there were abundant capillaries between the myocardial fibers. However, some animals had a common feature that the differentiation of the ventricles was delayed, the right ventricle was absent (n=3), and there was only a small cavity. The cavities of the left and right atria were slightly enlarged and almost normal (E3-3, E3-4). In an individual animal, the development of the heart was obviously delayed (n=1), the heart volume was small, the interventricular septum was lost, the right ventricle was absent, the tissue was solid, and there were no myocardial trabeculae. The left ventricle had a smaller cavity and only a small number of myocardial trabeculae on the inner wall. The left and right atria were atrophied and small (E3-5) (see Figure 20).
[0087] The statistical data is shown in Table 2 below. As can be seen, folic acid also affects the birth rate of rats, and at high doses it can decrease the birth rate.
[0088] [Table 2]
[0089] Experimental Example 9: Effects of pharmacological doses of folic acid on the fetal mouse heart To investigate the effect of pharmacological doses of folic acid on the fetal rat heart, the study was divided into folic acid groups (six groups) and blank controls, which were 4.555 mg / kg / d folic acid (group 1), 2.2775 mg / kg / d folic acid (group 2), 0.911 mg / kg / d folic acid (group 3), 0.4555 mg / kg / d folic acid (group 4), 0.22775 mg / kg / d folic acid (group 5), and 0.113875 mg / kg folic acid (group 6). The folic acid group and blank control were 4 pregnant mice per group, and 4.555 mg / kg / d (group 1), 2.2775 mg / kg / d folic acid (group 2), 0.911 mg / kg / d folic acid (group 3) were intraperitoneally administered, and 0.4555 mg / kg / d folic acid (group 4), 0.22775 mg / kg / d folic acid (group 5), 0.113875 mg / kg folic acid (group 6) were intragastrically administered, and the blank control was naturally reared. Seven days after administration to the female rats, the male and female rats were placed in the same cage in a 1:1 ratio and mated, and the vaginal plug was inspected the next morning. The day when the vaginal plug was observed was considered to be day 0 of pregnancy, and the pregnant rats were reared alone and continued to be administered for 21 days, and the fetuses were collected by Caesarean section, and the number of fetal rats in each group is shown in Figure 30. The hearts of the mice were collected and pathological examination was performed. The results were as follows:
[0090] As shown in the figure, in the 4.555 mg / kg group (group 1), the atria and ventricles were basically differentiated and formed, and no obvious pathological changes were observed in the pericardium, endocardium, epicardium, or myocardium. The development of the left and right atria was basically normal, the cross-section of the right atrium was generally slightly larger than the left atrium, and abundant myocardial trabeculae were observed on the inner wall of the cavity. In individual animals, the atrial cavity was small. The left and right ventricles were basically formed, the ventricular wall was rich in blood vessels, the left wall was thick, the cavity was narrow, and even in some cases, there was no obvious left ventricular cavity (n=3), or only closely arranged myocardial trabeculae were observed. The right ventricle of individual animals also showed cavity stenosis. It was also noted that the right ventricular wall was too thin in individual animals. All sections showed large vascular cavities connected to the ventricles, and some cross-sections showed valves within the lumen.
[0091] At 2.2775 mg / kg (Group 2), the ventricles and atria were essentially differentiated, the pericardium was intact, and the myocardium, epicardium, and endocardium were intact, without necrosis or infiltration of inflammatory cells. Abundant trabeculae were observed in the left and right atria, with only a small cross-section of the left atrium in an individual animal (Fig. 21d). An atrial septal defect was observed in an individual animal (Fig. 21d). The left and right ventricles were essentially developed, with abundant trabeculae in the ventricles, connected vascular cavities, and individual intravascular valves (Fig. 21b, e). Individual cross-sections showed the atrioventricular opening and mitral valve (Fig. 21d). Some animals had a defective left ventricle (n=2) or no obvious cavity and only sparse trabeculae (Fig. 21b, c). Some animals also had a thin right ventricular wall (Fig. 21b, d).
[0092] At 0.911 mg / kg (Group 3), the ventricles and atria were basically differentiated and formed, the pericardium was intact, and the myocardium, epicardium and endocardium were intact, without necrosis or infiltration of inflammatory cells. Both the left and right atria were filled, and the atria had abundant myocardial trabeculae. In some individual sections, only a small portion of the left atrium was observed (Fig. 22c, e). The left and right ventricles were almost fully developed, and in individual individuals, the left ventricular wall was thick and the cavity was narrow (Fig. 22d). The ventricular wall was abundantly vascularized, and abundant myocardial trabeculae were observed inside the ventricles. In most sections, large blood vessels connected to the ventricles and valvular structures within the lumen were observed (Fig. 22a, b, d, e). In individual sections, the mitral valve and right atrioventricular opening were observed (Fig. 22c). In individual individuals, the right ventricular wall was too thin (Fig. 22c, e). There was a defect in the individual atrial or ventricular wall (n=1).
[0093] At 0.4555 mg / kg (Group 4), the left and right atria had abundant trabeculae, and the atrial cross-sections were small. The left and right ventricular walls were thick, the cavities were narrow, the trabeculae were tightly arranged, and the ventricular walls were abundantly blood vessels. Individual rats had small ventricular cross-sections and deep staining.
[0094] At 0.22775 mg / kg (Group 5), the left and right atria had abundant myocardial trabeculae, the left and right ventricular walls were thick, the cavities were narrow, the myocardial trabeculae were closely arranged, and the ventricular walls were abundantly vascularized, and in some animals, the left ventricular cavity was not observed (n=5). The large blood vessels connected to the ventricles and the valves in the cavities were observed in most cross sections, but were not observed individually.
[0095] At 0.113875 mg / kg (Group 6), the ventricles and atria were basically differentiated and formed, the pericardium was intact, and only in individual sections were there no complete pericardium, myocardium, epicardium or endocardium, and no necrosis or infiltration of inflammatory cells was observed. Both the left and right atria were filled, and the atria had abundant myocardial trabeculae. Some animals had damaged atrial walls (n=1), and blood pooled in the pericardial cavity, without corresponding pathological changes, which may be related to sampling. Individual animals had small hearts. The left and right ventricles were abundant, and some animals had thick left ventricular walls and narrow left ventricular cavities. Individual animals had ventricular septal defects (n=3), right ventricular stenosis, or the right ventricular wall was too thin. The statistics for all folic acid groups were as follows:
[0096] [Table 3]
[0097] The sample size was small and could not be pooled statistically, but pathology showed that folic acid was associated with increased risk of ventricular and septal defects.
[0098] Experimental Example 10 Effects of folic acid and 5-methyltetrahydrofolate on fetal development in mice Seventy-five 7-week-old C57BL / 6J female mice and 25 8-week-old C57BL / 6J male mice were used, provided by Shanghai Lingchun Biological Science and Technology Co., Ltd., with the certificate number: SCXK (Shanghai) 2018-0003. After purchasing the animals, the female mice were adapted and raised for 10 days until they reached a weight of about 20 g and the male mice reached a weight of about 25 g, and the experiment was started after they became adults. The female mice were randomly divided into five groups according to weight, solvent control, 151.66 μg / kg folic acid, 303.32 μg / kg folic acid, 151.66 μg / kg 5-methyltetrahydrofolate calcium (folic acid equivalent), and 303.32 μg / kg 5-methyltetrahydrofolate calcium (folic acid equivalent). 1.1275 unit mass of 5-methyltetrahydrofolate calcium is equivalent to 1 unit mass of folic acid.
[0099] There were 15 mice per group, and they were numbered by finger-cutting. From the day after the groups were divided, the mice were intragastrically administered once a day. After one week of preliminary administration, male and female mice were placed in the same cage in a 3:1 ratio, and vaginal plugs were observed every day from the next day. The day when a vaginal plug was observed was considered to be day 0.5 of pregnancy. After 14 days in the same cage, administration to the female mice was stopped, the male mice were removed, and the pregnant female mice were kept alone until delivery.
[0100] Newborn mice were removed and weighed on the day of birth. A portion of newborn mice was randomly selected from each group and electrocardiograms were performed on the day of birth (NeoNatal Mouse, iWorx, Dover, NH, USA). In addition, 4 to 5 mice were randomly selected from each group, grown to 6 days of age, and subjected to small animal cardiac ultrasound examination (Vevo 2100 Imaging System, VisualSonics, Toronto, ON, Canada).
[0101] After the detection, the thoracic and abdominal cavities of the mice were opened, and the cardiac morphology and cardiac rate were observed under a stereomicroscope (SMZ 168, Motic, Xiamen, Fujian, China), and photographed and videotaped for recording (Motic Image Plus 3.0, Motic, Xiamen, Fujian, China). The mice were then killed, and the hearts, livers, kidneys, and lungs were collected. The hearts and livers of newborn mice from each group were collected, fixed in 4% paraformaldehyde, paraffin-embedded, sectioned, and stained with H&E. Half of the other tissues were immersed in RNA later and fixed, and the remaining half was directly immersed in liquid nitrogen and frozen for subsequent experiments.
[0102] The results are as follows:
[0103] Regarding the effect of folic acid on cardiac ultrasound in newborn mice, in the control (A), low-dose folic acid group (B), high-dose folic acid group (C), low-dose methyltetrahydrofolate group (D) and high-dose methyltetrahydrofolate group (E), based on basic knowledge of kinetics, B and C had significant differences in dynamic flow phase compared to the control, while D and E groups were relatively similar to the control. The ultrasound cardiogram of a 6-day-old newborn mouse is shown in Figure 23.
[0104] There was no significant difference in the ventricular septum end diastolic and end systolic thickness (mm) (A-B). The high-dose folic acid group had significantly lower left ventricular end diastolic and end systolic internal diameters (mm) than the other groups, and the difference between the left ventricular end diastolic internal diameter and the other groups was statistically significant (C, D). There was no significant statistical difference in ejection fraction and short-axis shortening fraction (%) between the groups (E, F). The ultrasound cardiogram data of 6-day-old newborn mice are shown in Figure 24. After euthanasia of 1-day-old newborn mice, the hearts were removed, fixed in 4% paraformaldehyde, embedded in paraffin, sliced, stained with H&E, and photographed under a conventional microscope. The myocardium of the newborn mice was intact in the control, low-dose methyltetrahydrofolate group, and high-dose methyltetrahydrofolate group. In the high and low-dose folate groups, small heart wall defects were observed in the left atrium and interventricular area of the newborn mice (B, C). As shown in Figure 25.
[0105] [Table 4]
[0106] Because the electrodes were only placed in contact with the skin of the newborn mice and not inserted subcutaneously as in adult mice, the signals measured were not stable and could not be statistically summarized.
[0107] These results indicate that calcium 5-methyltetrahydrofolate is incapable of directly inducing cardiac developmental malformations, and that folic acid may cause congenital heart disease.
[0108] Experimental Example 11 Prevention of cardiac malformations with calcium 5-methyltetrahydrofolate Transgenic zebrafish (fli-1:EFP) were purchased from the Model Animal Institute of Nanjing University. The fish used in the experiment were adult zebrafish less than one year old. The pH value of the rearing water was 7±0.2, the temperature was about 28°C, the light and dark time ratio was 14h:10h, and they were fed with fertile eggs twice a day. Three zebrafish (one female and two males) were placed in an egg-laying box the night before, and eggs were collected the next morning. The eggs were placed in embryo culture medium (prepared with 0.2g / L sea salt) and cultured at 28°C.
[0109] According to the literature survey, three different types of substances were selected that were reported to cause heart disease, namely ethanol, lead nitrate, and aristolochic acid, as shown in the following table.
[0110] [Table 5]
[0111] Zebrafish embryos were placed in 24-well plates from 2 hpf, administered drugs and cultured until 8 hpf, with 10 embryos per well. Drug solutions were added at the concentrations listed in the table above. The embryos were washed and then transferred to egg solution and cultured until 72 hpf. The embryos were immediately sorted when they died. Each group was tested three times.
[0112] The concentrations selected in the malformation prevention experiment with 5-methyltetrahydrofolic acid were recorded in a table. The malformation phenotype was observed, the number of all abnormal zebrafish with malformations was recorded, and the malformation rate and rescue rate of each group were calculated. Indicators such as morphological defects, heart rate, and heart morphology were observed and evaluated using an SMZ745T inverted stereo microscope.
[0113] 1) Prevention of lead nitrate-induced cardiac malformations by 5-methyltetrahydrofolic acid 2.4 mM Pb(NO3)2 could reduce the survival rate of embryos, but the addition of 10 mM L-5-MTHF-Ca could not rescue the effect of 2.4 mM Pb(NO3)2 on the survival rate of embryos. Compared with the control, the phenotypes of zebrafish embryos at different time points were evaluated. At 8 hpf, neither 2.4 mM Pb(NO3)2 nor 2.4 mM Pb(NO3)2 + 10 mM L-5-MTHF-Ca showed obvious embryonic developmental delay. At 24 hpf, 2.4 mM Pb(NO3)2 had no obvious effect on the development and growth of zebrafish, and zebrafish embryos had developed heads and tails, with tails showing a wagging phenomenon. At 48 hpf, 2.4 mM Pb(NO3)2 had no effect on the development of intersomite blood vessels in zebrafish, and there was no phenomenon of hydropericardium. At 72 hpf, 2.4 mM Pb(NO3)2 shortened the zebrafish body length and caused a large number of embryonic malformations, mainly trunk bending and tail shortening, but no significant difference was observed in the development of the subintestinal plexus vasculature. Meanwhile, 10 mM L-5-LMTHF-Ca could rescue the embryonic developmental malformations caused by 2.4 mM Pb(NO3)2 (see Figure 26).
[0114] To further quantitatively evaluate the rescue effect of 10 mM L-5-MTHF-Ca on Pb(NO3)2, we only evaluated the 10s heart rate of zebrafish embryos at 48 hpf and the body length of zebrafish between each group at 72 hpf, because no embryonic pericardial edema was observed. As shown in Figure 27, Pb(NO3)2 caused slow heart rate and short body length of zebrafish, and increased the rate of embryonic malformation, showing a significant concentration-dependence, while the group with 10 mM L-5-MTHF-Ca could rescue the malformation phenotype of zebrafish with slow heart rate, short body length, and abnormally curved trunk.
[0115] As described above, 10 mM L-5-MTHF-Ca can rescue all developmental malformations induced by 2.4 mM Pb(NO3)2 in zebrafish embryos.
[0116] 2) Prevention of alcohol-induced cardiac malformations with 5-methyltetrahydrofolic acid The 1.2% EtOH group had a significant difference in survival rate compared to the control, but the 1.2% EtOH + 10 mM L-5-MTHF-Ca group was able to rescue the survival rate, and the survival rate was not different from the control (Figure 28A). At 72 hpf, the morphology of zebrafish in the 0.6% and 0.9% EtOH groups was similar to that of the control, and 1.2% EtOH caused a defect in the development of subintestinal plexus vasculature in zebrafish, and the 1.2% EtOH + 10 mM L-5-MTHF-Ca group did not improve this defect (Figure 28B).
[0117] At 48 hpf, 0.9% EtOH and 1.2% EtOH groups had a deformed phenotype of slow heart rate in zebrafish embryos, but did not affect pigment growth and intersomitic vascular development. 0.9% and 1.2% EtOH + 10 mM L-5-MTHF-Ca alleviated the slow heart rate. At 48 hpf, each concentration of EtOH had a deformed phenotype of hydropericardium in zebrafish embryos, and adding 10 mM L-5-MTHF-Ca at a concentration of 0.6% could reduce the rate of hydropericardium. 1.2% EtOH + 10 mM L-5-MTHF-Ca group had no role in alleviating hydropericardium (see Figure 29).
[0118] In conclusion, ethanol caused malformation phenotypes in zebrafish embryos, including early embryonic growth retardation, hydropericardium, slow heart rate, shortened body length, and impaired development of the subintestinal plexus vascular system, without affecting pigmentation or intersegmental vascular development. The addition of 10 mM L-5-MTHF-Ca alleviated hydropericardium under low-concentration (0.6%) EtOH conditions, and alleviated shortening of body length under high-concentration (1.2%) EtOH conditions, and increased the survival rate of embryos. Under medium- and high-concentration (0.9%, 1.2%) EtOH conditions, L-5-MTHF-Ca significantly alleviated slow heart rate, and had a preventive effect on malformations.
[0119] 3) Preventive effect of 5-methyltetrahydrofolic acid on malformations caused by aristolochic acid A A model was created by selecting 1 to 5 μM aristolochic acid A, and a rescue test was simultaneously performed with 10 mM L-5-MTHF-Ca. It was found that 2 to 5 μM aristolochic acid A significantly reduced embryo viability, and the addition of 10 mM L-5-MTHF-Ca could rescue the effect of aristolochic acid A on embryo viability (Figure 30). However, for the high concentration aristolochic acid A group (5 μM), the rescue effect of L-5-MTHF-Ca was not significant.
[0120] When comparing with the control group, the phenotypes of zebrafish embryos at different time points were evaluated (see FIG. 31). At 8 hpf and 24 hpf, 1-5 μM aristolochic acid A and 1-5 μM aristolochic acid A + 10 mM L-5-MTHF-Ca did not show obvious embryonic growth retardation, malformation, or death. At 48 hpf, in the aristolochic acid A treatment group, the embryos gradually showed hydropericardium, slow heart rate, trunk bending, loss of systemic blood flow, blood pooling, opacification of the yolk sac, and other phenomena with increasing concentrations of aristolochic acid A, which became more severe with increasing concentrations of aristolochic acid A. At the same time, the high concentration group showed underdevelopment of intersegmental blood vessels. 10 mM L-5-MTHF-Ca could rescue the malformations such as hydropericardium, slow heart rate, and underdevelopment of intersegmental blood vessels caused by aristolochic acid A. At 72 hpf, aristolochic acid A-treated zebrafish showed a complete defect in the development of the subintestinal plexus vasculature and a shortened body length, but 10 mM L-5-MTHF-Ca could rescue the shortened body length and defective development of the subintestinal plexus vasculature induced by aristolochic acid A to some extent.
[0121] To further quantitatively evaluate the rescue effect of 10 mM L-5-MTHF-Ca on aristolochic acid A, the pericardial edema rate of zebrafish embryos at 48 hpf, 10s heart rate, and body length of zebrafish among groups at 72 hpf were evaluated. As can be seen from Figure 32, 1-5 μM aristolochic acid A caused pericardial edema, slow heart rate, and shortened body length in zebrafish, and the addition of 10 mM L-5-MTHF-Ca could rescue the malformation phenotypes of pericardial edema, slow heart rate, and shortened body length in zebrafish to some extent.
[0122] In conclusion, 10 mM L-5-MTHF-Can can rescue to some extent the developmental malformations and death of zebrafish embryos caused by 1 to 5 μM aristolochic acid A.
Claims
1. 1. Use of 5-methyltetrahydrofolic acid in the preparation of a drug or health food for preventing fetal cardiac malformation, The use, characterized in that the cardiac malformation is a cardiac malformation caused by ethanol, lead nitrate, or aristolochic acid.
2. The use according to claim 1, wherein the 5-methyltetrahydrofolic acid comprises 5-methyltetrahydrofolic acid or a pharma- ceutically acceptable salt thereof.
3. 2. The use of claim 1, wherein the 5-methyltetrahydrofolic acid comprises an optical isomer or a mixture of optical isomers of 5-methyltetrahydrofolic acid selected from 5-methyl-(6S)tetrahydrofolic acid, 5-methyl-(6R)tetrahydrofolic acid, or 5-methyl(6R,S)tetrahydrofolic acid.
4. The use according to claim 2, characterized in that the pharma- ceutically acceptable salts include corresponding acid addition salts converted from a basic group in 5-methyltetrahydrofolic acid, and corresponding base addition salts converted from an acidic group in 5-methyltetrahydrofolic acid.
